Navigation Links
Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
Date:12/4/2007

CLEVELAND, Dec. 4 /PRNewswire/ -- An independent panel of scientists has awarded Ganeden Biotech, Inc. self-affirmed GRAS (Generally Recognized as Safe) status for its patented probiotic, GanedenBC30 (Bacillus coagulans GBI- 30, 6086). After an extensive evaluation of research studies and toxicology data, the panel concluded that GanedenBC30 is safe for use as an ingredient in food products. According to the FDA, self-affirmed GRAS status is awarded to any substance that is generally recognized among qualified experts as having been adequately shown to be safe under the conditions of its intended use.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041213/CLM031LOGO )

"With so many health benefits and potential applications available for GanedenBC30, licensing partners now have one more level of confidence in the safety of GanedenBC30 as an ingredient," commented Ganeden's Founder and Chief Scientist, Sean Farmer. "Achieving GRAS status further supports our commitment to provide superior probiotic bacteria in widely available premium products," Farmer said.

GanedenBC30 (Bacillus coagulans GBI-30, 6086) is a high-survivability strain of the probiotic, Bacillus coagulans. In addition to food products, GanedenBC30 is currently used in a broad range of applications including dietary supplements, animal health products, feminine hygiene and topical applications. The probiotic cells in GanedenBC30 are able to survive very harsh manufacturing processes, do not require refrigeration and survive gastric acidity. Overall, GanedenBC30 has shown to be heartier than other probiotic strains and exhibits excellent stability, offering more flexibility in manufacturing and delivery systems.

"GanedenBC30 is different from other traditional bacteria because it is surrounded by a natural organic layer that serves as a protective shield against the manufacturing process, shelf life and stomach acids and intestinal bile," explains Farmer. "Because of this unique make-up, GanedenBC30 survives the hostile environment of the stomach, colonizes the intestines, and produces lactic acid, which are all critical factors to the success of a probiotic. That's why we initially chose a strain of Bacillus coagulans over other conventional probiotic strains," explained Farmer.

About Ganeden Labs

Established in 2006, Ganeden Labs is the licensing and development division of Ganeden Biotech, making proprietary, patented probiotic technology available for use in innovative products in a wide range of industries. Ganeden maintains an extensive intellectual property portfolio with patent and trademark protection for an array of technologies all over the world. GanedenBC30 and its related patents are available for license in a wide variety of applications. For more information, visit http://www.ganedenlabs.com.

About Ganeden Biotech

Founded in 1997, Ganeden Biotech Inc. is a consumer healthcare company based in Cleveland, Ohio that features a popular line of over-the-counter, products under the brand names Sustenex, Digestive Advantage, and Clearly Confident. Ganeden's oral products including Sustenex and Digestive Advantage contain GanedenBC30, a patented strain of Bacillus coagulans.


'/>"/>
SOURCE Ganeden Biotech
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... for North American hospitals, will present its chain-of-custody solution for tracking and securing ... Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... ALBANY, New York , November 30, 2016 /PRNewswire/ ... exceptionally consolidated as a few players hold a dominant ... Lonza Group, Charles River Laboratories International, Inc., and Merck ... global market in 2015. Transparency Market Research observes that ... they are focused on development products that are do ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
Breaking Biology News(10 mins):